They found that Nrf2 activation in monocytes/granulocytes, and endothelial cells ameliorates the pathophysiology of SCD, suggesting that targeting Nrf2 activation could be a plausible therapeutic approach to ameliorate SCD pathology [110]. Here, NFE2L2 is linked to Schnyder corneal dystrophy.